Letters to the Editor
- Catherine Lewis
- Aust Prescr 1995;18:73-5
- 1 January 1995
- DOI: 10.18773/austprescr.1995.005
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, Australian Prescriber has published information about fluticasone propionate in its New Drugs section (Aust Prescr 1994;17:74). This stated that caution is advised when changing from the dry powder to the aerosol form of fluticasone; however, clinical trials do not support this statement.1,2
Each inhalation from the metered dose inhaler is half the strength from the corresponding Diskhaler. Therefore, for a given dose, the patient inhales two puffs from the inhaler or the contents of one blister.
Clarification that the devices are clinically equivalent, dose for dose, would be appreciated as this may help to avoid confusion among prescribers regarding the interchangeability of these devices.
Allen & Hanburys
Allen & Hanburys, Boronia, Vic.